BeyondSpring's lead asset, plinabulin, continues to demonstrate clinical superiority
BeyondSpring reported clinical trial data on its novel lead asset, Plinabulin. In a head-to-head Phase 2 trial comparing Plinabulin with Neulasta® (pegfilgrastim) was shown to be effective in significantly reducing docetaxel-induced thrombocytopenia over different timepoints. September 25, 2018